Crossmark

Targeting EGFR in Lung Cancer: Current Standards and Developments

Crossref DOI link: https://doi.org/10.1007/s40265-018-0916-4

Published Online: 2018-06-18

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Díaz-Serrano, Asunción

Gella, Pablo

Jiménez, Elisabeth

Zugazagoitia, Jon

Paz-Ares Rodríguez, Luis
Funding

Funding for this research was provided by:

Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (ES) and European Social Fund (PEJD16/2016/BMD-2715)

Instituto de Salud Carlos III (CM15/00196)

Sistema Nacional de Salud

Universidad Complutense de Madrid
License Information

Text and Data Mining valid from 2018-06-01
More Information

Article History

First Online: 18 June 2018

Compliance with Ethical Standards

:

: No external funding was used in the preparation of this manuscript.

: Luis Paz-Ares has received consulting fees or honorarium from Roche, AstraZeneca, Pfizer, Boehringer Mannheim, Lilly, MSD, Merck, Novartis, and Astellas. Asunción Díaz-Serrano, Pablo Gella, Elisabeth Jiménez, and Jon Zugazagoitia declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.